OncoGenex Pharmaceuticals Inc.
1522 217th Place SE
Suite 100
Bothell
Washington
98021
United States
Tel: 425-686-1500
Fax: 425-686-1600
Website: http://www.oncogenex.com/
About OncoGenex Pharmaceuticals Inc.
OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. We have a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development.We currently have five product candidates in development: OGX-011, OGX-427, SN2310, CSP-9222 and OGX-225. Three of the products are in clinical development.
We have conducted five phase 2 clinical trials to evaluate the ability of OGX-011 to enhance the effects of therapy in prostate, non-small cell lung and breast cancer.
In December 2009, we announced that we entered into a Collaboration and License Agreement with Teva Pharmaceutical Industries, for the development and global commercialization of OGX-011. In connection with the Collaboration Agreement, OncoGenex and Teva developed a Clinical Development Plan under which the following three phase 3 clinical trials will be initiated:
• a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer; • a phase 3 clinical trial of OGX-011 in approximately 800 patients with first-line castrate resistant prostate cancer; and • a phase 3 clinical trial of OGX-011 in at least 700 patients with first-line non-small cell lung cancer.
We have reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of two Phase 3 registration trials of OGX-011 in patients with CRPC via the Special Protocol Assessment (SPA) process.
Learn more about OncoGenex at www.oncogenex.com
US Operations: Suite 100, 1522 217th Place SE, Bothell, WA 98021. Phone (425) 686-1500
Canadian Operations: Suite 400 – 1001 West Broadway, Vancouver, BC V6H 4B1. Tel: (604) 736-3678
YEAR FOUNDED:
October 1991
LEADERSHIP:
Founders: Martin Gleave and Scott Daniel Cormack
CEO and Founder: Scott Cormack
CMO (Medical): Cindy Jacobs
CFO: John Bencich
JOBS:
Please click here for.
CLINICAL TRIAL:
Please click here for clinical trial information.
FOLLOW ONCOGENEX:
Tweets by OncoGenex
208 articles about OncoGenex Pharmaceuticals Inc.
-
FDA Grants Additional Fast Track Designation for OncoGenex Pharmaceuticals Inc.'s OGX-011 in Combination with First Line Chemotherapy
10/6/2009
-
OncoGenex Pharmaceuticals Inc. to Webcast Presentations at September Investor Conferences
9/3/2009
-
OncoGenex Pharmaceuticals Inc. Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
8/13/2009
-
OncoGenex Pharmaceuticals Inc. Announces Issuance of Key Patent for OGX-011
8/10/2009
-
OncoGenex Pharmaceuticals Inc. Reports Second Quarter 2009 Financial Results
8/7/2009
-
OncoGenex Pharmaceuticals Inc., Rising from Obscurity, Scopes Out Partners to Develop Prostate Cancer Drug
8/5/2009
-
OncoGenex Pharmaceuticals Inc. Completes $9.5 Million Registered Direct Offering
7/24/2009
-
OncoGenex Pharmaceuticals Inc. to Raise $9.5 Million Through Sale of Common Stock
7/21/2009
-
OncoGenex Pharmaceuticals Inc. Files Shelf Registration Statement
6/30/2009
-
OncoGenex Pharmaceuticals Inc. Added to Russell Indexes
6/30/2009
-
OncoGenex Pharmaceuticals Inc. Gets FDA Nod for Prostate Cancer Trial Design
6/24/2009
-
OncoGenex Pharmaceuticals Inc. to Webcast American Society of Clinical Oncology Reception on May 30, 2009
5/27/2009
-
OncoGenex Pharmaceuticals Inc. to Webcast American Society of Clinical Oncology Reception on May 30, 2009
5/27/2009
-
OncoGenex Pharmaceuticals Inc. Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
5/15/2009
-
OncoGenex Pharmaceuticals Inc. Reports First Quarter Financial Results
5/7/2009
-
OncoGenex Pharmaceuticals Inc. to Release First Quarter Financial Results
4/30/2009
-
OncoGenex Pharmaceuticals Inc. Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
4/28/2009
-
OncoGenex Pharmaceuticals Inc. Named Life Sciences Company of the Year by LifeSciences British Columbia
4/10/2009
-
OncoGenex Pharmaceuticals Inc. to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
3/4/2009
-
OncoGenex Pharmaceuticals Inc. Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
2/4/2009